Dove期刊
期刊
会议
图书
作者:Yan Zhang , Ruihua Wei ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2015, Vol.2015 (default), pp.3413-3421Dove
摘要:Choroidal neovascularization (CNV) secondary to pathologic myopia has a very high incidence in global, especially in Asian, populations. It is a common cause of irreversible central vision loss, and severely affects the quality of life in the patients with pathologic myopia....
作者:Yan Zhang , Qin Liu ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2016, Vol.2016 (default), pp.3501-3507Dove
摘要:Post-surgical adhesion formation is the most common complication in abdominal and pelvic surgery. Adhesiolysis is the most common applied treatment for adhesion formation but is often followed by adhesion reformation. Therefore, an efficient strategy should be adopted to sol...
作者:Yan Zhang , Wen-bin Qiao , Li Shan
来源:[J].OncoTargets and Therapy(IF 2.073), 2018, Vol.2018 (default), pp.3385-3393Dove
摘要:Objectives: The forkhead box protein M1 (FOXM1) is a key member of the FOX transcription factor family, which plays a vital role in a series of physiological processes. In the present study, NSCLC patients and cell lines were studied to explore the correlation between FOXM1 expre...
作者:Yan Zhang , Rong Zhu ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2014, Vol.2014 (default), pp.1277-1286Dove
摘要:Background: Concanavalin A (Con A) is well known as an inducer of T cell-mediated hepatitis, especially in the model of autoimmune hepatitis. Apoptosis and autophagy has been shown to contribute to cell death in autoimmune hepatitis. Hydrogen sulfide (H2S) is the third most ...
作者:Yan Zhang , Wenxia Lu ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2015, Vol.2015 (default), pp.2757-2766Dove
摘要:Background: Although the effectiveness of treatment with ursodeoxycholic acid (UDCA) and fenofibrate for primary biliary cirrhosis (PBC) has been suggested by small trials, a systematic review to summarize the evidence has not yet been carried out.Methods: A meta-analysis of...
作者:Yan Zhang , Li Kong ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2015, Vol.2015 (default), pp.2767-2770Dove
摘要:Malignant pericardial effusion (MPCE) is a common complication of advanced malignant tumors and interferes severely with patient prognosis and quality of life. The standard treatment for this complication is intracavitary perfusion of chemotherapeutic drugs, which is limited by u...
作者:Yan Zhang , Miao Jiang
来源:[J].International Journal of Nanomedicine(IF 3.463), 2015, Vol.2015 (default), pp.7359-7370Dove
摘要:Carboxymethyl–β-cyclodextrin (CMβ-CD) modified glycol chitosan (GCS) nanoparticles (GCS-CMβ-CD NPs) were synthesized and its pH-sensitive drug-release properties were investigated. GCS-CMβ-CD NPs could encapsulate doxorubicin hydrochloride (DOX), and the encapsulation e...
作者:Yan Zhang , Feifei Teng ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (default), pp.489-502Dove
摘要:Lung cancer is the leading cause of cancer death in males and the second in females worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because of locally advanced or metastatic...
作者:Yan Zhang , Gang Liu ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (default), pp.1303-1310Dove
摘要:Objective: Transcription factor Zinc finger E-box-binding homeobox 1 (ZEB1), as one of the key inducers of epithelial-mesenchymal transition, has been reported to be regulated by microRNA-144 and Bcl-2-associated athanogene 3 which both promote thyroid cancer cell invasion. Howev...
作者:Yan Zhang , Yu Xiong ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (default), pp.4037-4041Dove
摘要:BackgroundThe efficacy and safety of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been studied worldwide. However, there are few reports directly comparing the efficacy and safety between icotinib and docetaxel as second-line treatment in lung ad...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×